GE-Genometrix: Dx Imaging Meets Genomics
In an intriguing deal, GE Medical Systems, one of the largest suppliers of MRI and PET equipment, is teaming up with Genometrix, Inc., an applied genomics company in a research collaboration that will combine molecular imaging techniques with genetic probes to develop technologies for detecting and quantifying risk levels for diseases such as breast and prostate cancer.
You may also be interested in...
With a surge in interest in molecular imaging, GE Medical Systems has been on the prowl for new technologies that improve performance of its PET and SPECT systems, so that clinicians can obtain information at the subcellular level. Amersham Health, too, has been been looking for better systems to help improve distribution and performance of its radiopharmaceutical labeling agents. Now the two are joining forces to create a next-generation compound for PET using new, easier-to-use chemistries.
Genometrix has developed a protoype molecular imaging system it believes can demonstrate single molecule detection at a 10-fold throughput advantage over conventional technologies used in sequence-, hybridization-, and amplification-based DNA research and diagnostics protocols.
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.